W H Kruit|G Stoter - JoVE Visualize

Showing results (1-10 of 206) with videos related to

Pageof 21

Sort By:

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001

Interferon-alpha induced Raynaud's syndromeW H Kruit, A M Eggermont, G Stoter

Cancer Immunology, Immunotherapy : CII|September 4, 1999

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cellsW H Kruit, P I Schmitz, G Stoter

European Journal of Clinical Investigation|April 12, 2000

Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.

British Journal of Cancer|November 21, 1998

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patientsR de Wit, W H Kruit, G Stoter, et al.

Journal of the National Cancer Institute|October 2, 1996

Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.

Breast Cancer Research and Treatment|May 1, 1995

Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancerM Bontenbal, A S Planting, J Verweij, et al.

British Journal of Cancer|June 1, 1995

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanomaW H Kruit, S H Goey, F Calabresi, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor responseW H Kruit, R L Bolhuis, S H Goey, et al.

Cancer|November 15, 1994

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complicationW H Kruit, K J Punt, S H Goey, et al.

British Journal of Cancer|September 1, 1996

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanomaW H Kruit, C J Punt, S H Goey, et al.

Pageof 21

Showing results (1-10 of 206) with videos related to

Sort By:

Pageof 21

Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 6, 2001

Interferon-alpha induced Raynaud's syndromeW H Kruit, A M Eggermont, G Stoter

Cancer Immunology, Immunotherapy : CII|September 4, 1999

The role of possible risk factors for acute and late renal dysfunction after high-dose interleukin-2, interferon alpha and lymphokine-activated killer cellsW H Kruit, P I Schmitz, G Stoter

European Journal of Clinical Investigation|April 12, 2000

Intrapleural administration of tumour necrosis factor-alpha (TNFalpha) in patients with mesothelioma: cytokine patterns and acute-phase protein responseT C Stam, A J Swaak, W H Kruit, et al.

British Journal of Cancer|November 21, 1998

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patientsR de Wit, W H Kruit, G Stoter, et al.

Journal of the National Cancer Institute|October 2, 1996

Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor supportR de Wit, J Verweij, M Bontenbal, et al.

Breast Cancer Research and Treatment|May 1, 1995

Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancerM Bontenbal, A S Planting, J Verweij, et al.

British Journal of Cancer|June 1, 1995

Final report of a phase II study of interleukin 2 and interferon alpha in patients with metastatic melanomaW H Kruit, S H Goey, F Calabresi, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1993

Interleukin-2-induced thyroid dysfunction is correlated with treatment duration but not with tumor responseW H Kruit, R L Bolhuis, S H Goey, et al.

Cancer|November 15, 1994

Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complicationW H Kruit, K J Punt, S H Goey, et al.

British Journal of Cancer|September 1, 1996

Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanomaW H Kruit, C J Punt, S H Goey, et al.

Pageof 21